Therapeutic potential of ADAR1-regulated macrophage exosomes for improving myocardial damage in septic cardiomyopathy
Quick Facts
- Publication title: Therapeutic potential of ADAR1-regulated macrophage exosomes for improving myocardial damage in septic cardiomyopathy
- Journal: J Nanobiotechnology
- Year: 2026
- DOI: 10.1186/s12951-026-04368-4
- PMID/PMCID: 41965774; PMC13200382
Research overview
Our study reveals a novel ADAR1-miR-122-XIAP axis in macrophage exosomes that protects against sepsis-induced myocardial injury, offering a potential disease modulation strategy for SICM. The molecular mechanisms that underlie SICM remain elusive, and effective therapies are limited.
Key findings
Here, we report a pivotal role for adenosine deaminases acting on RNA-1 (ADAR1) in modulating macrophage polarization and exosome-mediated intercellular communication, which ameliorates myocardial damage in SICM.
We determined that ADAR1 overexpression in macrophages promotes an anti-inflammatory M2 phenotype, reduces myocardial inflammation, and inhibits cardiomyocyte apoptosis in a murine model of sepsis.
Mechanistically, ADAR1 regulates the level of microRNA-122 (miR-122) in macrophage-derived exosomes.
Exosomal miR-122 targets X-linked inhibitor of apoptosis protein (XIAP), modulating cardiomyocyte survival.
Echo Biotech Role
Echo Biotech contributed cargo loading; the study also used or cited ExoLoad®.
Related platforms: Echosome®, Research Reagents & Tools
Related services and capabilities: Small RNA / Cargo Loading, Research Reagent / Product Supply
Related products or reagents: ExoLoad® Nucleic Acid Loading Kit
References
Original publication: Therapeutic potential of ADAR1-regulated macrophage exosomes for improving myocardial damage in septic cardiomyopathy Journal of nanobiotechnology. 2026. DOI: 10.1186/s12951-026-04368-4. PMID/PMCID: 41965774; PMC13200382.